RETHINK-ALZ
Simufilam 100 mg for Mild to Moderate Alzheimer’s Disease
Inclusion Criteria
- Alzheimer’s Disease
- **other criteria will apply
For more information, call Tatiana Jimenez-Knight at 716-961-9219 or email tjimenezknight@dentinstitute.com. You can also visit: https://rethink-alz.com/
Subscribe To Our Newsletter
Sign up to receive email updates on announcements, new services added, company updates & more!
Want to participate in a study?
Fill out the form below and one of our Research Coordinators will be in contact with you as soon as possible. If we currently do not have a study that is currently available for you, we will add you to our database for future studies.